Post-operative Imaging in High Grade Glioma: is Management Influenced?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-07-20

Study Completion Date

2022-12-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Magnetic resonance imaging (MRI) is likely to play an important role in the management of high grade glioma. Appropriate and timely neuroimaging in the follow up period is believed to be crucial in making subsequent management decisions. However, there is a paucity in the literature providing evidence to support this. The aim of this study is to determine whether neuroimaging performed at each component of the patient pathway after initial high grade glioma treatment, actually results in a real change in management (as opposed to a perceived change in management). The main emphasis is on all imaging used at the time of a MDM, however, we will also study specifically dynamic susceptibility contrast-enhanced (DSC) MRI and dynamic contrast enhanced (DCE) MRI.

The study is in the format of Mock MDMs to be compatible with real life decision making. Using retrospective identical information available at the MDM i.e. compiled recent correspondence, histopathological and molecular information, the MDM members (oncology nurse, oncologist, neurosurgeon, neuroradiologist, pathologist/molecular scientist) will prospectively determine the patient management with and without the imaging.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Image Guided Therapy in the Treatment of Gliomas

NCT01263821

Glioma

TERMINATED NA

Improving Surgical Outcomes in Patients With Low Grade Gliomas Using Advanced Pre- and Intra-operative MRI

NCT02884947

Brain Neoplasms

COMPLETED

Advanced MR Techniques in Detection of Tumor Infiltration and Grading in Gliomas

NCT01225003

Gliomas

COMPLETED

FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy

NCT03370926

Glioblastoma Multiforme Anaplastic Astrocytoma Radiotherapy

UNKNOWN

Automatic Segmentation MRI Cerebral Glioma

NCT04674579

Cerebral Glioblastoma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

KCH patients

75 high grade glioma patients from KCH

MRI

Intervention Type OTHER

Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC

NHNN patients

75 high grade glioma patients from NHNN

MRI

Intervention Type OTHER

Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MRI

Structural MR (T2, FLAIR, T1 and T1+C), DCE, DSC

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven HGG patients (Grade III and IV WHO criteria)
* Underwent surgery, radiotherapy and chemotherapy regimen according to 2018 NICE guidelines (1)
* \>=18 years old
* Has follow-up MRI imaging (T1, T2, FLAIR and T1 with contrast enhancement) and also DSC and DCE imaging
* Evaluated at MDT meetings between March 2018 and March 2020.